Learn how CASGEVY, the first NHS-approved CRISPR gene therapy, treats sickle cell disease through a revolutionary genetic ...

Last month, the NICE endorsed Casgevy for use in the NHS under a managed access scheme to treat sickle cell disease.

When Vijay Sankaran was an MD-PhD student at Harvard Medical School in the mid-2000s, one of his first clinical encounters ...

a few months after turning it down for sickle cell disease. Final draft guidance published this morning clears Casgevy (exagamglogene autotemcel) as an option for people 12 years and over with ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access ...

While there is plenty of excitement about the new gene editing treatment, Casgevy, some in the sickle-cell community say they have been let down before and worry about being let down again.

Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success ...

Sickle cell disease changes adult beta-globin ... The first of the gene therapies, commercially called Casgevy, works by removing and inactivating a gene that is normally responsible for producing ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Undergoing a bone marrow transplant during adolescence, but not in adulthood, may lower the risk of stroke with SCD, a mouse ...

announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel).